The Platin-X Series: Activation, Targeting, and Delivery

Overview

Journal Dalton Trans

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2016 Aug 6

PMID 27493131

Citations 21

Authors

Uttara Basu

Bhabatosh Banik

Ru Wen

Rakesh K Pathak

Shanta Dhar

Affiliations

Soon will be listed here.

Abstract

Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for the "magic bullet" which can satisfy the requirements of an effective chemotherapeutic drug formulation. Pt(iv) complexes are kinetically more inert than the Pt(ii) congeners and offer the opportunity to append additional functional groups/ligands for prodrug activation, tumor targeting, or drug delivery. The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs. Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery. In this review, we will address the attempts made in our lab to develop Pt(iv) prodrugs that can be activated and delivered using targeted nanotechnology-based delivery platforms.

Citing Articles

A Dual Action Platinum(IV) Complex with Self-assembly Property Inhibits Prostate Cancer through Mitochondrial Stress Pathway.

Nafees M, Hanif M, Muhammad Asif Khan R, Faiz F, Yang P ChemMedChem. 2024; 19(22):e202400289.

PMID: 39380183 PMC: 11581420. DOI: 10.1002/cmdc.202400289.

Pt(iv) derivatives of cisplatin and oxaliplatin bearing an EMT-related TMEM16A/COX-2-selective dual inhibitor against colorectal cancer cells HCT116.

Ma Z, Ding X, Zhu Z, Chen Q, Wang D, Qiao X RSC Med Chem. 2024; .

PMID: 39185449 PMC: 11342162. DOI: 10.1039/d4md00327f.

Intersection of Inorganic Chemistry and Nanotechnology for the Creation of New Cancer Therapies.

Shah A, Surnar B, Kolishetti N, Dhar S Acc Mater Res. 2023; 3(3):283-296.

PMID: 37091880 PMC: 10117633. DOI: 10.1021/accountsmr.1c00178.

Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.

Barth M, Hafner N, Runnebaum I, Weigand W Int J Mol Sci. 2023; 24(6).

PMID: 36982792 PMC: 10056020. DOI: 10.3390/ijms24065718.

The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CHCOO)Cl(NH)(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake.

Gabano E, Zanellato I, Pinton G, Moro L, Ravera M, Osella D Bioinorg Chem Appl. 2023; 2022:3698391.

PMID: 36620349 PMC: 9822769. DOI: 10.1155/2022/3698391.

References

Goto S, Iida T, Cho S, Oka M, Kohno S, Kondo T . Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res. 2000; 31(6):549-58. DOI: 10.1080/10715769900301121. View

Kolb H, Finn M, Sharpless K . Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl. 2001; 40(11):2004-2021. DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5. View

Thun M, Henley S, Patrono C . Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002; 94(4):252-66. DOI: 10.1093/jnci/94.4.252. View

Dolman R, Deacon G, Hambley T . Studies of the binding of a series of platinum(IV) complexes to plasma proteins. J Inorg Biochem. 2002; 88(3-4):260-7. DOI: 10.1016/s0162-0134(01)00360-9. View

Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Rosenberg B, VANCAMP L, KRIGAS T . INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE. Nature. 1965; 205:698-9. DOI: 10.1038/205698a0. View

Ang W, Khalaila I, Allardyce C, Juillerat-Jeanneret L, Dyson P . Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc. 2005; 127(5):1382-3. DOI: 10.1021/ja0432618. View

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

10.

Papapoulos S . Bisphosphonate actions: physical chemistry revisited. Bone. 2006; 38(5):613-6. DOI: 10.1016/j.bone.2006.01.141. View

11.

Yang Z, Schumaker L, Egorin M, Zuhowski E, Guo Z, Cullen K . Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res. 2006; 12(19):5817-25. DOI: 10.1158/1078-0432.CCR-06-1037. View

12.

Gotte M, Yip G . Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006; 66(21):10233-7. DOI: 10.1158/0008-5472.CAN-06-1464. View

13.

Margiotta N, Ostuni R, Ranaldo R, Denora N, Laquintana V, Trapani G . Synthesis and characterization of a platinum(II) complex tethered to a ligand of the peripheral benzodiazepine receptor. J Med Chem. 2007; 50(5):1019-27. DOI: 10.1021/jm0612160. View

14.

Cullen K, Yang Z, Schumaker L, Guo Z . Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr. 2007; 39(1):43-50. DOI: 10.1007/s10863-006-9059-5. View

15.

Berger I, Nazarov A, Hartinger C, Groessl M, Valiahdi S, Jakupec M . A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. ChemMedChem. 2007; 2(4):505-14. DOI: 10.1002/cmdc.200600279. View

16.

Sasanelli R, Boccarelli A, Giordano D, Laforgia M, Arnesano F, Natile G . Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12. J Med Chem. 2007; 50(15):3434-41. DOI: 10.1021/jm061435l. View

17.

Hall M, Mellor H, Callaghan R, Hambley T . Basis for design and development of platinum(IV) anticancer complexes. J Med Chem. 2007; 50(15):3403-11. DOI: 10.1021/jm070280u. View

18.

Jeong Y, Kim S, Jin S, Ryu H, Jin Y, Jung T . Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci. 2007; 97(3):1268-76. DOI: 10.1002/jps.21103. View

19.

Mukhopadhyay S, Barnes C, Haskel A, Short S, Barnes K, Lippard S . Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug Chem. 2007; 19(1):39-49. PMC: 2505196. DOI: 10.1021/bc070031k. View

20.

Kratz F, Muller I, Ryppa C, Warnecke A . Prodrug strategies in anticancer chemotherapy. ChemMedChem. 2007; 3(1):20-53. DOI: 10.1002/cmdc.200700159. View